Robert Uger is CSO at Trillium Therapeutics Inc. (TRIL). They have made 3 open-market trades across 1 company since 2021, most recently 2021-07-07.
CIK 0001838047
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TRIL | 3,646 | $70K |
Shares reported on the most recent Form 4, priced at the 2021-07-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRIL | SELL · 10b5-1 | 2021-07-07 | 2021-07-09 | $9.00 | $33K | -8.3% | -24.9% | +109.0% |
| TRIL | SELL · 10b5-1 | 2021-06-07 | 2021-06-09 | $8.27 | $30K | +0.6% | -15.9% | +71.5% |
| TRIL | SELL · 10b5-1 | 2021-05-07 | 2021-05-11 | $9.30 | $34K | -8.0% | +7.7% | -28.7% |
| TRIL | SELL · 10b5-1 | 2021-04-07 | 2021-04-09 | $10.82 | $39K | -7.8% | -11.6% | -17.7% |
| TRIL | SELL · 10b5-1 | 2021-03-12 | 2021-03-15 | $11.97 | $35K | -7.7% | -8.2% | -12.5% |
| TRIL | SELL · 10b5-1 | 2021-03-08 | 2021-03-10 | $10.11 | $37K | -6.7% | -12.2% | -18.4% |
| TRIL | SELL | 2021-02-08 | 2021-02-10 | $12.71 | $174K | -11.5% | -10.9% | -32.5% |
| TRIL | SELL · 10b5-1 | 2021-01-11 | 2021-01-13 | $15.20 | $9K | -15.0% | -9.4% | -31.0% |
| TRIL | SELL | 2021-01-08 | 2021-01-12 | $15.71 | $134K | -10.2% | -7.6% | -31.1% |
| TRIL | SELL | 2021-01-07 | 2021-01-11 | $14.75 | $108K | -11.9% | -8.7% | -32.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.